NEW YORK — Proteomics International Laboratories said on Friday that it has signed an agreement for the distribution of its Promarker D diabetic kidney disease immunoassay in Italy.
The CE-marked ELISA-based test, called Promarker D (IA), uses protein signatures in blood to detect the onset of kidney disease in type 2 diabetics. It is a high-throughput version of the Australian company's mass spectrometry-based PromarkerD (MS) test.
Under the terms of the two-year deal, Medical Horizons SRL will have the exclusive right to distribute the immunoassay in Italy, with Proteomics International receiving an undisclosed payment on the sale of each test. Medical Horizons will be responsible for registering the test with the Italian Ministry of Health.
Additional terms were not disclosed.
"Previously we focused on the more sophisticated mass spectrometry test, but the release of this easy-to-use, higher-throughput immunoassay platform opens up many more market opportunities," Proteomics International Managing Director Richard Lipscombe said in a statement. "We can enter into more traditional distribution agreements with proven companies like Medical Horizons."